GSK in the clear

Panadol Osteo pricing statement ambiguous, but not false or misleading: ACCC  The Australian Competition and Consumer Commission has concluded its investigation into whether GlaxoSmithKline (GSK) made misleading statements about a price increase of its Panadol Osteo products. The watchdog adjudged it was “unlikely to establish a contravention of the Australian Consumer Law” had occurred in